

Coagulation Treatment

Reference Number: RDF1925-23

Date of Response: 27/10/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Under the Freedom of Information (FOI) Act 2000 I would like to obtain the following information:

1. *In the last 3 months (July, August, and September 2023), how many Haemophilia A, Haemophilia B and von Willebrand patients were treated in your trust with the following coagulation factors:*

Answer: Please see table below. In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤ 5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

| | | |
|----|--|----------|
| a. | <i>Hemlibra (non-inhibitor patients)</i> | Nil |
| b. | <i>Hemlibra (inhibitor patients)</i> | Nil |
| c. | <i>Advate</i> | ≤ 5 |
| d. | <i>Adynovi</i> | Nil |
| e. | <i>Elocta</i> | ≤ 5 |
| f. | <i>Esperoct</i> | Nil |
| g. | <i>NovoEight</i> | Nil |
| h. | <i>ReFacto AF</i> | ≤ 5 |
| i. | <i>Nuwiq</i> | Nil |
| j. | <i>Idelvion</i> | Nil |
| k. | <i>Refixia</i> | Nil |
| l. | <i>Alprolix</i> | ≤ 5 |
| m. | <i>BeneFIX</i> | ≤ 5 |
| n. | <i>Replenine</i> | Nil |
| o. | <i>Rixubis</i> | Nil |
| p. | <i>Voncento</i> | ≤ 5 |
| q. | <i>Veyvondi</i> | Nil |

| | | |
|----|------------------|-----|
| r. | <i>Wilate</i> | ≤5 |
| s. | <i>Willfact</i> | Nil |
| t. | <i>Alphanate</i> | Nil |
| u. | <i>Octanate</i> | Nil |
| v. | <i>Optivate</i> | Nil |
| w. | <i>Fahndi</i> | Nil |
| x. | <i>Haemate</i> | Nil |

2. *In the last 3 months (July, August, and September 2023), how much volume in IU or mg was used of the following coagulation factors:*

Answer: Please see table below.

| | | |
|----|--|----------|
| a. | <i>Hemlibra (non-inhibitor patients)</i> | Nil |
| b. | <i>Hemlibra (inhibitor patients)</i> | Nil |
| c. | <i>Advate</i> | 19,000iu |
| d. | <i>Adynovi</i> | Nil |
| e. | <i>Elocta</i> | 57,500iu |
| f. | <i>Esperoct</i> | Nil |
| g. | <i>NovoEight</i> | Nil |
| h. | <i>ReFacto AF</i> | 31,000iu |
| i. | <i>Nuwiq</i> | Nil |
| j. | <i>Idelvion</i> | Nil |
| k. | <i>Refixia</i> | Nil |
| l. | <i>Alprolix</i> | 57,000iu |
| m. | <i>BeneFIX</i> | 2,000iu |
| n. | <i>Replenine</i> | Nil |
| o. | <i>Rixubis</i> | Nil |
| p. | <i>Voncento</i> | 1,200iu |
| q. | <i>Veyvondi</i> | Nil |
| r. | <i>Wilate</i> | 4,000iu |
| s. | <i>Willfact</i> | Nil |
| t. | <i>Alphanate</i> | Nil |
| u. | <i>Octanate</i> | Nil |
| v. | <i>Optivate</i> | Nil |
| w. | <i>Fahndi</i> | Nil |
| x. | <i>Haemate</i> | Nil |

3. *In the last 3 months (July, August, and September 2023), how many patients switched from one of the following products to any other brand? Please indicate the brand that was switched to (i.e. Advate: 2 switches to Hemlibra, 3 switches to Elocta)*

Answer: Please see table below.

| | | |
|----|--|-------------------|
| a. | <i>Hemlibra (non-inhibitor patients)</i> | ≤5 swap to Advate |
| b. | <i>Hemlibra (inhibitor patients)</i> | Nil |
| c. | <i>Advate</i> | Nil |
| d. | <i>Adynovi</i> | Nil |
| e. | <i>Elocta</i> | Nil |
| f. | <i>Esperoct</i> | Nil |

| | | |
|-----------|-------------------|-----|
| <i>g.</i> | <i>NovoEight</i> | Nil |
| <i>h.</i> | <i>ReFacto AF</i> | Nil |
| <i>i.</i> | <i>Nuwig</i> | Nil |
| <i>j.</i> | <i>Idelvion</i> | Nil |
| <i>k.</i> | <i>Refixia</i> | Nil |
| <i>l.</i> | <i>Alprolix</i> | Nil |
| <i>m.</i> | <i>BeneFIX</i> | Nil |
| <i>n.</i> | <i>Replenine</i> | Nil |
| <i>o.</i> | <i>Rixubis</i> | Nil |
| <i>p.</i> | <i>Voncento</i> | Nil |
| <i>q.</i> | <i>Veyvondi</i> | Nil |
| <i>r.</i> | <i>Wilate</i> | Nil |
| <i>s.</i> | <i>Willfact</i> | Nil |
| <i>t.</i> | <i>Alphanate</i> | Nil |
| <i>u.</i> | <i>Octanate</i> | Nil |
| <i>v.</i> | <i>Optivate</i> | Nil |
| <i>w.</i> | <i>Fahndi</i> | Nil |
| <i>x.</i> | <i>Haemate</i> | Nil |